A standardized multidisciplinary approach to treating posthemorrhagic ventricular dilation, or PHVD, in extremely preterm infants is showing significant clinical promise.
Researchers at a tertiary care center implemented a standardized PHVD pathway in 2021, focusing on consistent measurements and earlier intervention thresholds. The study, covering infants treated between 2017 and 2023, compared outcomes before and after the pathway was adopted.
Results showed that after implementation, median maximum anterior horn width fell from 32 mm to 26 mm. The ventricular index also dropped, from 18 mm to 15 mm. These reductions suggest the pathway helps limit ventricular enlargement before more permanent cerebrospinal fluid diversion is required.
More critically, among 74 infants followed for at least 18 months, the rate of death or severe cerebral palsy dropped from 62% before the pathway to 33% after-a 29% reduction.
Ventricular size proved to be a strong predictor of outcomes. Each 1 mm increase in maximum anterior horn width was linked to 9% higher odds of death or severe cerebral palsy. The odds rose to 14% for each 1 mm increase before shunt placement.
The findings support earlier, standardized intervention for PHVD. Larger multicenter studies are now needed to confirm whether these results can be replicated across other neonatal care settings.